This shows that IgA and IgM reactivity to LPS puts a patient with IBD at a greater risk for damage to the gut barrier, including disruption of zonulin/occludin, which can result in consequences and manifestations beyond the gastrointestinal tract [89]. The gene discussed is HP; the disease is irritable bowel syndrome.